{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
m sofosbuvir
to a specific field?
Status:
Possibly Marketed Outside US
Source:
ANDA210822
(2018)
Source URL:
First approved in 1988
Source:
ANDA212506
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
BLA125296
(2011)
Source URL:
First approved in 1986
Source:
ANDA070994
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
NDA207947
(2015)
Source URL:
First approved in 1981
Source:
ANDA087479
Source URL:
Class:
POLYMER
Status:
US Approved Rx
(2014)
First approved in 2006
Source:
GARDASIL by MERCK AND CO INC DIV MERCK SHARP AND DOHME
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
US Approved Rx
(1989)
First approved in 1989
Class:
STRUCTURALLY DIVERSE
Status:
US Approved Rx
(2013)
First approved in 1942
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT04353518: Phase 3 Interventional Unknown status COVID-19
(2020)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT04387760: Phase 2 Interventional Completed SARS-CoV 2
(2020)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT03554109: Phase 2 Interventional Withdrawn Triple Negative Breast Cancer (TNBC)
(2018)
Source URL:
Class:
STRUCTURALLY DIVERSE
